An observational study in Coronary Disease, sponsored by Bon-Kwon Koo. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Bon-Kwon Koo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.
Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2020, is one of 20 observational ones, and was the 41st registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seung-Whan Lee, M.D., Ph.D. · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 20+
Young-Hak Kim, MD, PhD · Sites in Korea, Republic of
Ages 20+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,100 is above the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 1,000 across the 29 interventional studies, 1,125 across the 20 observational. Of the 34 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 49 have an industry lead sponsor. The 10 most frequent:
Bon-Kwon Koo is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Bon-Kwon Koo has 2 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT05529459Seung-Whan Lee, M.D., Ph.D.Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Coronary Disease with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Percutaneous coronary intervention (PCI) is a standard treatment strategy for coronary artery disease (CAD). With the presence of myocardial ischemia, PCI reduces the risks of death, myocardial infarction (MI) and revascularization compared to medical therapy. However, the risk of future clinical events remains high, and about 10% of patients experienced further cardiovascular events after PCI. Several factors are associated with these poor outcomes. Well known patient-related risk factors are diabetes mellitus, chronic kidney disease, left ventricular dysfunction, previous MI, and presentation with the acute coronary syndrome. Procedure-related factors, such as stent underexpension, malapposition, edge dissection, the number of the used stent, and total stent length, are also related to poor prognosis after PCI. Recent studies reported that fractional flow reserve (FFR) after coronary stenting, or post PCI FFR, was associated with future clinical outcomes after PCI, and low post PCI FFR value was associated with procedural factors. However, optimal cut-off values of post-PCI FFR ranged widely, from 0.86 to 0.96, and some study reported the limited prognostic value of post-PCI FFR. This might result from differences in study populations, the definition of outcomes, type of stent used, and distribution of included vessels among previous studies.
To establish the clinical relevance of post-PCI FFR and to evaluate the useful cut-off value of post-PCI FFR in daily practice, investigators planned to incorporate all previous evidence of post-PCI FFR by collaboration with international researchers.
This study population was incorporated from studies which were already published. Investigators will incorporate all known registries to the POST-PCI FLOW registry by requesting data from principal investigator of each registry.
Investigators will perform systemic review of the previous published data and an updated patient-level meta-analysis of studies, including the most recent publications. PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes of Health registry of clinical trials, and relevant websites were searched for pertinent published studies. The electronic search strategy was complemented by manual examination of references cited by included articles, recent reviews, editorials, and meta-analyses. No restrictions were imposed on language, study period, or sample size. Searching key words included 'post', 'after', 'PCI', 'Percutaneous coronary intervention', 'coronary stenting', 'stenting', 'stent', 'stent implantation', 'FFR', and 'fractional flow reserve'.
Patients who were diagnosed as obstructive coronary artery disease and treated by DES and measured post PCI FFR after PCI.
Articles were included when they met the following prespecified criteria: (1) included the patients who underwent PCI with drug-eluting stent (DES); (2) post-PCI FFR was measured after DES implantation; (3) pre-PCI FFR measurement was not mandatory for article inclusion; (4) patients were followed up at least 6 months; (5) clinical outcomes, including all-cause death, cardiac death, target vessel myocardial infarction (TVMI) or target vessel revascularization (TVR), were clearly reported; (6) randomized controlled trials or non-randomized prospective or retrospective registries were included. Two independent investigators screened titles and abstracts, identified duplicated studies, performed full-article reviews, and determined the studies' inclusion. The third investigator supervised the searching process and adjudicated all the disagreements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
Device: Percutaneous coronary intervention
PCI was performed using drug-eluting stents
Target vessel failure
A composite of cardiac death, target vessel myocardial infarction and target vessel revascularization
Time frame: 2 years
Cardiac death or myocardial infarction
a composite of cardiac death and target vessel myocardial infarction
Time frame: 2 years
Target vessel myocardial infarction
Time frame: 2 years
Target vessel revascularization
Time frame: 2 years
Cut-off value of post-PCI FFR
Define the best cut-off value for predicting the future adverse events
Time frame: 2 years
Plan to share: Undecided
Started May 2020 (actual). Primary completion is estimated for Feb 2021, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bon-Kwon Koo